Improving CAR T-cell and monoclonal antibody treatment through epitope editing

In a paper, “Epitope editing enables targeted immunotherapy of acute myeloid leukaemia,” published in Nature, researchers at the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, introduce a genetic alteration to donor hematopoietic stem/progenitor cells (HSPCs) that allows them to survive immunotherapy treatment for acute myeloid leukemia (AML).